newsfilter
← Latest News
Business Wire·

Arrivo BioVentures Announces Positive Results from qEEG and BNA™ Study of SP-624 on Neural Brain Activity Related to Depression and Cognition

Findings show significant brain activity after a single 20mg dose of SP-624 in healthy subjects Phase 2b/3 study of SP-624 in major depressive disorder is underway SP-624 has the potential to be the first treatment